Neuroendocrine carcinoma of the gallbladder
Neuroendocrine carcinoma is a rare, fast-growing form of gallbladder cancer made of small cell or large cell hormone-type cells, often mixed with ordinary adenocarcinoma. It is usually advanced when found and median survival in the largest series was six to seven months. It is treated like other high-grade neuroendocrine carcinomas rather than like gallbladder adenocarcinoma.
Overview
Gallbladder neuroendocrine carcinomas were characterised in 2026 from 31 cases among 636 gallbladder cancers: 7 pure small cell, 2 pure large cell and 22 mixed with an adenocarcinoma component (the neuroendocrine part averaging 80 percent of the tumour). The female to male ratio was 5.2 to 1 and median age 58, seven years younger than ordinary gallbladder cancer; high-grade glandular dysplasia was present in 15, six arising in intracholecystic papillary neoplasms. Median Ki-67 was 70 percent, lymphovascular invasion was seen in 74 percent and perineural invasion in 56 percent; 72 percent were pT3 or pT4 against 26 percent of ordinary cancers. Synaptophysin was positive in 95 percent, chromogranin in 75 percent and CD56 in 90 percent; the pRB/p16 pathway was inactivated in 83 percent and p53 was mutant-pattern in 89 percent. Median survival was 6.1 months, with a few unexpectedly long survivors (Reid 2026). In SEER (287 cases, 1975 to 2016) the incidence was 1.6 percent of gallbladder carcinomas, the male to female ratio 1 to 2, median survival 7 months, and one, two, three and five-year overall survival 36.6, 17.8, 13.2 and 7.3 percent; serum chromogranin A was proposed as a marker (Cai 2022). Cancer Research UK lists small cell (oat cell) carcinoma and neuroendocrine tumours among the rare types and notes they are not necessarily treated like adenocarcinoma.
What differs in treatment: these are managed as poorly differentiated neuroendocrine carcinomas of the digestive tract, with platinum and etoposide chemotherapy rather than gemcitabine and cisplatin, and surgery for the minority with localised disease; a population-based analysis found surgery and adjuvant chemotherapy each associated with better survival (Khan 2023, J Pers Med, doi 10.3390/jpm13061009). Mixed tumours are treated according to the higher-grade neuroendocrine component. Well-differentiated neuroendocrine tumours of the gallbladder are a separate, far less aggressive group covered on the neuroendocrine pages.
State of the art
Red cards
From the labels and guidelines behind the standard of care. Your team's thresholds win.- Emergency services nowBleeding or bruising
Bleeding that will not stop, black or bloody stools, or unexplained bruising when platelets are expected to be low.
- Check before combiningKidneys: Cisplatin
Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).
See all on the product pages:Cisplatin·Printable cards in the navigator
Anatomy and lymph node drainage
- Pancreatic head (most PDAC)
- Body and tail
- Ampulla
- Islets (pancreatic NET)
- Intrahepatic ducts
- Perihilar (Klatskin)
- Distal bile duct
- Gallbladder
- Nodes: peripancreatic
- Nodes: hepatic hilar
- Nodes: coeliac and superior mesenteric
Most pancreatic cancers arise in the head next to the bile duct, which is why jaundice is the presenting sign; bile duct cancers are named by where along the tree they sit.
- Pancreatic head (most PDAC)
- Body and tail
- Ampulla
- Islets (pancreatic NET)Small cell neuroendocrine carcinoma of the gallbladder · Large cell neuroendocrine carcinoma of the gallbladder · Mixed neuroendocrine and non-neuroendocrine neoplasm of the gallbladder (adenocarcinoma plus neuroendocrine carcinoma) · Well-differentiated neuroendocrine tumour of the gallbladder (separate, low grade)
- Intrahepatic ducts
- Perihilar (Klatskin)
- Distal bile duct
- GallbladderSmall cell neuroendocrine carcinoma of the gallbladder · Large cell neuroendocrine carcinoma of the gallbladder · Mixed neuroendocrine and non-neuroendocrine neoplasm of the gallbladder (adenocarcinoma plus neuroendocrine carcinoma) · Well-differentiated neuroendocrine tumour of the gallbladder (separate, low grade)
- peripancreatic
- hepatic hilar
- coeliac and superior mesenteric
Same organ: Pancreatic ductal adenocarcinoma, Biliary tract cancer (cholangiocarcinoma), Intrahepatic cholangiocarcinoma, Extrahepatic cholangiocarcinoma (perihilar and distal), Biliary tract cancer (all types), Neuroendocrine tumours, Pancreatic neuroendocrine tumours, Grade 3 well-differentiated neuroendocrine tumour, Extrapulmonary neuroendocrine carcinoma, Gallbladder cancer, Gallbladder adenocarcinoma, Papillary carcinoma of the gallbladder, Mucinous carcinoma of the gallbladder, Adenosquamous and squamous carcinoma of the gallbladder, Incidental gallbladder cancer (found after cholecystectomy), Carcinoma in situ and dysplasia of the gallbladder, Cystic duct carcinoma, Ampullary cancer (ampulla of Vater), Resectable pancreatic ductal adenocarcinoma, Borderline resectable pancreatic ductal adenocarcinoma, Locally advanced unresectable pancreatic ductal adenocarcinoma, Metastatic pancreatic ductal adenocarcinoma, KRAS G12C-mutant pancreatic ductal adenocarcinoma, KRAS wild-type pancreatic ductal adenocarcinoma, BRCA or PALB2-mutant pancreatic ductal adenocarcinoma, Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, Pancreatic acinar cell carcinoma, Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors, Pancreatoblastoma
Under 5 percent of gallbladder cancers in a 636-case pathology cohort (Reid 2026), 1.6 percent of gallbladder carcinomas in SEER (Cai 2022) and 3.3 percent of gallbladder neoplasms in the US National Cancer Database 2011 to 2020 (Louis 2025).
Cases by country
No country-level case numbers. This cancer is not mapped to a GLOBOCAN site.
One section per setting: the options named, what each is for, the trials behind them, the recorded trade-offs and the questions to ask.
Resection as for gallbladder cancer where feasible; surgery and adjuvant chemotherapy were each associated with better survival in population data.
Platinum and etoposide chemotherapy as for other extrapulmonary neuroendocrine carcinomas, rather than the gemcitabine and cisplatin used for adenocarcinoma.
Subtypes & biomarkers
top- Small cell neuroendocrine carcinoma of the gallbladder
- Large cell neuroendocrine carcinoma of the gallbladder
- Mixed neuroendocrine and non-neuroendocrine neoplasm of the gallbladder (adenocarcinoma plus neuroendocrine carcinoma)
- Well-differentiated neuroendocrine tumour of the gallbladder (separate, low grade)
- Synaptophysin, chromogranin A and CD56 on immunohistochemistry
- Ki-67 proliferation index (median 70 percent)
- Loss of pRB or p16 and mutant-pattern p53
- Serum chromogranin A (proposed)
- Share of neuroendocrine versus adenocarcinoma component
How often this target appears
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 1 changes by month →What is in development for Neuroendocrine carcinoma of the gallbladder, drawn from the whole corpus: 0 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Nothing recorded in development for this cancer yet.
Open problems and what is being done
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Expert centres
topExpert centres
These are the things we can measure; they are not a ranking of quality. Each column is a field on the institution record or a count over what OnCo has linked; a centre that treats many patients with Neuroendocrine carcinoma of the gallbladder but is thinly recorded here will look small.
Not known: OnCo holds no case-volume or outcome figures for centres, so none are shown. Where a national audit or registry publishes them, the centre's page links to it. Default order: Newsweek rank, then trials for this cancer, then research output.
Questions to ask
topQuestions to ask your oncologist about Neuroendocrine carcinoma of the gallbladder
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Why: Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example Synaptophysin, chromogranin A and CD56 on immunohistochemistry, Ki-67 proliferation index, Loss of pRB or p16 and mutant-pattern p53, Serum chromogranin A, Share of neuroendocrine versus adenocarcinoma component), and what were the results?Why: These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Why: Recognised subtypes for this cancer include Small cell neuroendocrine carcinoma of the gallbladder, Large cell neuroendocrine carcinoma of the gallbladder, Mixed neuroendocrine and non-neuroendocrine neoplasm of the gallbladder.
- Is germline (inherited) genetic testing recommended for me or my family?Why: Inherited variants can change treatment and matter for relatives.
Localised disease
- For my situation (localised disease), which of the standard options do you recommend and why?Why: Guideline options include: Resection as for gallbladder cancer where feasible; surgery and adjuvant chemotherapy were each associated with better survival in population data.
Advanced disease
- For my situation (advanced disease), which of the standard options do you recommend and why?Why: Guideline options include: Platinum and etoposide chemotherapy as for other extrapulmonary neuroendocrine carcinomas, rather than the gemcitabine and cisplatin used for adenocarcinoma.
- Am I a candidate for Cisplatin, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Why: Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Why: Supportive care improves quality of life and helps patients complete treatment.
Newly diagnosed? Read the first 60 days with Neuroendocrine carcinoma of the gallbladder, then print the one-page appointment sheet with room for the answers.
Print this page for your appointment (your browser's print command). These prompts are for discussion; your clinical team knows your case.
Direct links plus the targets, companies, and technologies of this cancer's products.
technologies
2drugs
1companies
1terms
4Latest papers
topQuery for this cancer: (TITLE:"Neuroendocrine carcinoma of the gallbladder" OR ABSTRACT:"Neuroendocrine carcinoma of the gallbladder" OR TITLE:"Small cell carcinoma of the gallbladder" OR ABSTRACT:"Small cell carcinoma of the gallbladder" OR TITLE:"Oat cell carcinoma of the gallbladder" OR ABSTRACT:"Oat cell carcinoma of the gallbladder" OR TITLE:"Large cell neuroendocrine carcinoma of the gallbladder" OR ABSTRACT:"Large cell neuroendocrine carcinoma of the gallbladder" OR TITLE:"Mixed neuroendocrine non-neuroendocrine neoplasm of the gallbladder" OR ABSTRACT:"Mixed neuroendocrine non-neuroendocrine neoplasm of the gallbladder" OR TITLE:"MiNEN" OR ABSTRACT:"MiNEN") AND (treatment OR therapy OR trial OR survival OR diagnosis). Results are unfiltered search hits about Neuroendocrine carcinoma of the gallbladder, not a curated reading list.
Similar pages
not linked directly; found by shared links- CancerMucinous carcinoma of the gallbladder
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary, subtype-page.
- CancerPapillary carcinoma of the gallbladder
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary, subtype-page.
- CancerCarcinoma in situ and dysplasia of the gallbladder
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary, subtype-page.
- CancerCystic duct carcinoma
Shares Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary, subtype-page.
- CancerIncidental gallbladder cancer (found after cholecystectomy)
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary, subtype-page.
- TermT2a versus T2b gallbladder cancer (peritoneal side versus hepatic side)
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary.
- TermSegment IVb and V liver resection (versus wedge resection)
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary.
- TermSimple cholecystectomy
Shares Gallbladder adenocarcinoma, Radical (extended) cholecystectomy, Gallbladder cancer and the tags gallbladder, biliary.